KLRD1 and colorectal carcinoma: Therefore, antibodies blocking inhibitory NK cell receptors might be advantageous to improve cetuximab-mediated ADCC [54] and the use of cytokines such as IL2 and IL15 has previously been shown to restore NK cell functionality in CRC patients [45,55].